Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Anthem Biosciences is a Bengaluru-based contract research, development and manufacturing organisation (CRDMO) serving global innovator pharma and biotech clients across small molecules and biologics, with capabilities spanning synthetic chemistry and fermentation. It also manufactures specialty ingredients such as probiotics, enzymes, peptides and nutritional actives. It listed via IPO in July 2025; revenue is driven by integrated discovery-to-commercial CRDMO contracts with high customer stickiness.
One of India's few integrated CRDMOs with both chemistry and fermentation platforms at scale.
Anthem Biosciences Ltd. is a constituent of NIFTY 500, NIFTY MIDCAP 150. See where it sits on the market heatmap →
Consolidated annual figures taken from Anthem Biosciences Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 |
|---|---|
| EPS (basic, ₹) | 0.00 |
| Book value / share (₹) | 54.16 |
| Return on equity | 19.4% |
| Return on capital employed | 22.6% |
| Operating margin | 32.9% |
| Net margin | 27.9% |
| EBITDA | ₹834 Cr |
| Free cash flow | ₹633 Cr |
| Total debt | ₹51 Cr |
| Debt to equity | 0.02 |
| Interest coverage | 101.5 |
| Current ratio | 5.54 |
| Shares outstanding | 56,17,15,000 |
Open the full income statement, balance sheet and cash flow for ANTHEM →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.